Earnings Call Summary | ENTOURAGE HEALTH CORP(ETRGF.US) Q1 2024 Earnings Conference
Earnings Call Summary | ENTOURAGE HEALTH CORP(ETRGF.US) Q1 2024 Earnings Conference
The following is a summary of the Entourage Health Corp. (ETRGF) Q1 2024 Earnings Call Transcript:
以下是Entourage Health Corp.（ETRGF）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Entourage Health Corp. reported a first-quarter revenue of $16.4 million, indicating a 9% year on year growth and a 23% sequential increase from the Q4 revenue in 2023.
Gross profit recorded a significant improvement, rising by 92% year on year to achieve a record gross margin of 45%.
The company was able to significantly reduce costs per unit via scaling operations and marked an increase in EBITDA by over $4 million, indicating their first quarter of positive EBITDA.
Entourage Health Corp. 報告稱，第一季度收入爲1,640萬美元，同比增長9％，較2023年第四季度收入連續增長23％。
毛利潤大幅改善，同比增長92％，達到創紀錄的45％的毛利率。
該公司得以通過擴大業務規模顯著降低單位成本，並使息稅折舊攤銷前利潤增長了400多萬美元，這表明其第一季度息稅折舊攤銷前利潤爲正。
Business Progress:
業務進展：
The company made significant strides in brand impact, product optimization, automation, and market penetration.
The launch of the Dime Bag brand was successful, with rapid growth reported in Ontario and Alberta.
Investments in pre-roll automation have considerably enhanced production capabilities.
The company continues to lead in the medical sector, with Starseed maintaining a stable patient population.
Furthermore, there are plans in place to introduce new products in international markets as part of their growth strategy.
該公司在品牌影響力、產品優化、自動化和市場滲透率方面取得了長足的進步。
Dime Bag品牌的推出取得了成功，安大略省和艾伯塔省報告了快速增長。
對卷前自動化的投資大大增強了生產能力。
該公司繼續在醫療領域處於領先地位，Starseed保持穩定的患者群體。
此外，還計劃在國際市場上推出新產品，作爲其增長戰略的一部分。
More details: ENTOURAGE HEALTH CORP IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。